Clinical Trials Logo
  1. Home
  2. Severe Sepsis
  3. NCT02413541
  4. Details
NCT02413541 Clinical Trial

The Pilot Study of the Efficacy of Polymyxin-B Hemoperfusion in Critically Ill Patients With Severe Sepsis

Severe Sepsis Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02413541
Other study ID # IRB.575/56
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date August 30, 2017

Study information
Verified date March 2021
Source Chulalongkorn University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research project is a study to immunology changes in critically ill patients with severe sepsis by using Endotoxin Activity Assay (EAA) combined with Polymyxin-B Hemoperfusion.

Recruitment information / eligibility
Status Completed
Enrollment 90
Est. completion date August 30, 2017
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - SIRS Criteria > or = 2 meets definition - Source of infection > or = 1 meet definition - Evidence of organ dysfunction > or = 1 meet definition Exclusion Criteria: - WBC < 5,000 /ul - Platelet < 30,000 / ul - Pregnancy woman - Advance stage cancer patients (terminally ill) who is refuse to be resuscitated - Received blood transfusion > 5 units in 24 hrs - Allergy to Polymyxin-B - High risk and uncontrolled bleeding - Organ transplant patients - On immunosuppressive agents within 2 weeks before study - HIV infection

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Polymyxin-B Hemoperfusion
Endotoxin removal
• Standard treatment

Locations
Country Name City State
Thailand Sasipha Tachaboon Bangkok Pathumwan

Sponsors (1)
Lead Sponsor Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

Outcome
Type Measure Description Time frame Safety issue
Primary Functions of cell surface markers CD11b expression on PMN and HLA-DR expression on monocyte 3 days
Primary Chemotaxis Neutrophil function 3 days
Primary EAA level Endotoxin level 3 days
Secondary Survival rate 28 days
Secondary Sequential Organ Failure Assessment (SOFA Score) 28 days
Secondary Acute Kidney Injury and Renal Replacement Therapy incidences 28 days
Secondary ICU length of stay 28 days
Secondary Mechanical ventilation free day 28 days
See also
  Status Clinical Trial Phase
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Completed NCT02539147 - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis N/A
Completed NCT01929772 - German Lactat Clearance in Severe Sepsis N/A
Completed NCT01932814 - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful? N/A
Completed NCT01449721 - Preemptive Resuscitation for Eradication of Septic Shock N/A
Active, not recruiting NCT01162109 - Zinc Therapy in Critical Illness Phase 1
Not yet recruiting NCT01211899 - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock N/A
Completed NCT00934011 - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections N/A
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00463645 - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients N/A
Completed NCT02361528 - GM-CSF to Decrease ICU Acquired Infections Phase 3
Completed NCT02734550 - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis N/A
Completed NCT02973243 - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Completed NCT01945983 - Early Use of Norepinephrine in Septic Shock Resuscitation N/A
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A